CDKN2A and acute lymphoblastic leukemia: Another interesting finding of our study was the fact that the presence of CDKN2A/2B deletions served as an important prognostic marker in B-ALL (EFS 65.3% vs. 93.6% for the non-deleted B-ALL subgroup, p < 0.001), but the prognostic effect was not statistically significant within the T-ALL cohort (EFS 64.3 vs. 69.2, p = 0.947).